



SHUKRA
PHARMACEUTICALS LTD.

14th February, 2020

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Scrip Code: 524632

Dear Sir/Madam,

SUB: - OUTCOME OF BOARD MEETING

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 14th February, 2020 at 03.00 p.m. and concluded at 08.00 p.m.:-

1. Considered, adopted and approved Unaudited Financial Results for the quarter ended on 31st December, 2019.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited

Arpita Shah
Company Secretary & Compliance officer

Email id: info@shukrapharmaceuticals.com Website: www.shukrapharmaceuticals.com

CIN : L24231GJ1993PLC019079




SHUKRA

PHARMACEUTICALS LTD.

Financial results by company					
PART I					(Rs. in Lakhs)
Statement of Standalone Unaudited Results for the Quarter Ended 31/12/2019					
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous year ended
	(31/12/2019)	(30/09/2019)	(31/12/2018)	(31/12/2019)	(31/03/2019)
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from Operation	388.03	288.65	114.37	781.02	569.15
II Other income	0.26	0.00	0.10	0.26	0.51
III Total Revenue (I + II)	388.29	288.65	114.47	781.28	569.66
IV Expenses					
(a) Cost of materials consumed	164.68	127.46	8.39	307.36	137.05
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(38.47)	0.00	0.00	(46.51)	(15.96)
(d) Employee benefits expense	134.22	95.72	54.79	301.11	196.01
(e) Finance Cost	0.00	0.00	0.00	0.07	0.06
(f) Depreciation and amortisation expense	35.05	35.49	18.42	85.75	96.26
(g) Other expenses	32.62	27.50	28.64	70.77	77.26
Total expenses	328.10	286.17	110.24	718.55	490.68
V Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)	60.19	2.48	4.23	62.73	78.98
VI Exceptional items	0.00	0.00	0.00	0.00	0.00
VII Profit / (Loss) before extraordinary items and tax (V - VI)	60.19	2.48	4.23	62.73	78.98
VIII Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX Profit before tax (VII- VIII)	60.19	2.48	4.23	62.73	78.98
X Tax expense - Provision for taxation	18.06	0.00	4.16	18.82	32.70
XI Net Profit / (Loss) for the period (IX-X)	42.13	2.48	0.07	43.91	46.28
XII Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
Items that will not be reclassified to Profit or Loss: Remeasurement of defined benefits plans (net of tax)					
XIII Total Comprehensive Income) (after tax) for the period	42.13	2.48	0.07	43.91	46.28
XIV Paid up Equity Share Capital (Face value of Re. 10/- each)	156.57	156.57	156.57	156.57	156.57
XV Other Equity excluding revaluation reserve	1443.14	1401.01	1388.07	1443.14	1400.47
XVI Earnings per equity share:					
(I) Basic	2.69	0.16	0.00	2.80	2.96
(2) Diluted	2.69	0.16	0.00	2.80	2.96

Email id: info@shukrapharmaceuticals.com Website: www.shukrapharmaceuticals.com

CIN : L24231GJ1993PLC019079





SHUKRA

PHARMACEUTICALS LTD.

NOTES:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 14th February 2020. The statutory auditors have carried out a limited review of the results for the quarter ended 31st December, 2019 and have expressed an unqualified audit
2. The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
3. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards)
4. The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations,
5. The Company is operating in single segment, so above results are for single segment only.

Date: 14.02.2020

Place: Ahmedabad

For and on behalf of the Board of Directors

NK Patel

Nilesh Kumar Patel

Director (DIN: 08316887)



Email id: info@shukrapharmaceuticals.com Website: www.shukrapharmaceuticals.com

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE' Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.
Factory Add. 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


**Review Report to
The Board of Directors of
Shukra Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Shukra Pharmaceuticals Limited (the 'Company') for the quarter ended December 31, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIRJCFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SIZE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place: Ahmedabad
Date: 14/02/2020**



**For, B J Trivedi & Associates,
Chartered Accountants
FRN 111042W**


**Bharat Trivedi
Proprietor
M. No. 039595
UDIN: 20039595AAAAAE3756**